Download Diplomate of National Board (DNB) 2020 December ClInIcal Haematology Paper III Question Paper
NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2020
CLINICAL HAEMATOLOGY
PAPER-III
Time: 3 hours
HEMAT/D/20/48/III
Max. Marks:100
Important Instructions:
You are provided with 5 answer sheet booklets. Each individual answer sheet booklet consists
of 10 pages excluding the covering jackets.
Answers to all the questions must be attempted within these 5 answer sheet booklets which
must be later tagged together at the end of the exam.
No additional supplementary answer sheet booklet will be provided.
Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. A 50-year-old lady presents with back pain and anemia.
4+3+3
a) Describe the approach to such a patient to rule out plasma cell disorder
in this patient with notes on the differential diagnosis.
b) Describe the ISS, R-ISS and mSMART risk stratification criteria.
c) Describe the management of relapsed refractory multiple myeloma.
2. a) Recommendations for thromboprophylaxis in pregnancy in patients
4+3+3
with past history of post-partum thrombosis.
b) Describe Global tests of coagulation.
c) Reasons for and against thrombophilia testing.
3. a) Mechanism of resistance to Tyrosine Kinase inhibitors in CML and
5+5
strategies to overcome the resistance.
b) Clinical & biologic factors associated with Treatment Free Remission
in CML.
4. a) Briefly mention the current status of Gene therapy for Hemophilia.
4+3+3
b) What are obstacles for using AAV vector for above?
c) Which alternative gene therapy approach showing promises recently?
5. a) Enumerate and briefly describe the chief characteristics of all the types
3+3+4
of vaccination available for SARS-CoV-2 in India and abroad.
b) What would be the recommendations of vaccination against SARS-
CoV-2 in various groups of benign and malignant hematological
diseases.
P.T.O.
c) Cytotoxic T cell infusion against any viral infections.
-1-
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.
FINAL EXAM
NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2020
CLINICAL HAEMATOLOGY
PAPER-III
6. A 40-year-old male presenting with fever and cervical lymphadenopathy
4+3+3
a) Role of Brentuximab in the management of Hodgkin's lymphoma.
b) Double hit and Double expresser lymphomas.
c) Role of autologous transplant in peripheral T cell lymphomas.
7. A 29-year-old man presents with fever, pancytopenia and coagulation
3+2+5
abnormalities with Auer rods in peripheral smear. Discuss:
a) Prognostic role of FLT3 mutation and other cytogenetic variants in
acute promyelocytic leukaemia (APML).
b) Role of autologous transplant in APML.
c) Various chemotherapy regimens with brief highlight on anthracycline
free double differentiating agents in APML.
8. a) Describe the role of flowcytometric and genetic markers in 3+4+3
prognosticating newly diagnosed chronic lymphocytic leukaemia.
b) Risk stratified therapy for chronic lymphocytic leukaemia.
c) Role of Allogeneic stem cell transplantation in the management of
chronic lymphocytic leukaemia.
9. a) Revised WHO 2016 diagnostic criteria for Polycythaemia Vera and
5+5
management guidelines.
b) IPSS-R risk stratification of myelofibrosis and management based on
risk stratification.
10. a) Immunotherapy in acute lymphoblastic leukaemia.
4+3+3
b) BCR-ABL-like acute lymphoblastic leukaemia.
c) Role of stem cell transplant in acute lymphoblastic leukaemia.
*************
-2-
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.
This post was last modified on 31 July 2021